Spirometric Grading
Spirometry Input
Post-Bronchodilator Parameters
Measured Value
Calculated as (Measured FEV1 / Predicted FEV1) × 100
Assessment Required
Enter the post-bronchodilator FEV1 % predicted to determine the spirometric grade of airflow limitation according to GOLD guidelines.
Guidelines & Evidence
Verified
Last Review: 2026-07-09
When to Use
Primary Indications
Confirming diagnosis of COPD (post-bronchodilator FEV1/FVC < 0.70)
Classifying severity of airflow obstruction in patients with established COPD
Guiding initial pharmacological therapy (stepped approach based on GOLD stage)
Monitoring disease progression over time (annual spirometry recommended)
Prognostic stratification (in combination with symptom scores and exacerbation history)
Research inclusion criteria for clinical trials of COPD therapies
Eligibility assessment for pulmonary rehabilitation, lung volume reduction, and transplant
Clinical Utility
GOLD staging provides a universal language for COPD severity based on FEV1% predicted. Stage 1 (mild) and Stage 2 (moderate) comprise 70-80% of COPD patients, while Stage 3 (severe) and Stage 4 (very severe) have higher mortality and exacerbation risk. However, GOLD staging alone is insufficient for treatment decisions - the 2023 update recommends combined assessment (GOLD stage + symptom score + exacerbation history) to assign patients to Groups A, B, or E. FEV1 remains the strongest single predictor of mortality, but adding dyspnea (CAT or mMRC) and exacerbation history improves treatment matching.
GOLD Stages vs Combined Assessment Groups
GOLD Stages 1-4 (spirometry only) are NO LONGER used alone for treatment decisions. Current GOLD 2023-2024 uses the "ABCD" assessment (now simplified to A, B, and E groups): Group A = low symptoms, low exacerbation risk; Group B = high symptoms, low exacerbation risk; Group E = high exacerbation risk (regardless of symptoms). FEV1 stage still predicts mortality and guides non-pharmacologic therapies (surgery, transplant).
Limitations of GOLD Staging Alone
Poor correlation with symptoms - two patients with GOLD Stage 2 (FEV1 50-80%) may have dramatically different dyspnea (mMRC 0 vs mMRC 4)
Does not incorporate exacerbation history - frequent exacerbators have worse outcomes regardless of FEV1%
Weak predictor of quality of life (explains only 15-20% of SGRQ variance)
Age and sex effects - older patients and women may have lower FEV1% without proportionate impairment
Race-specific reference equations required (NHANES III, GLI-2012) to avoid misclassification
Excludes non-spirometric domains (BMI, exercise capacity, comorbidities) captured by BODE index
Last Comprehensive Review: 2026